The global Dendritic Cell Cancer vaccine market was valued at $XX Mn in 2019 and is expected to reach $XX Mn in 2027 at a CAGR of XX%.
Market Introduction and Overview
The past decade has seen tremendous developments and breakthroughs in novel cancer therapies. Emerging new techniques, which target specific cancer cells and their intrinsic pathways are a boon for cancer patients. Current immunotherapies and precision medicines are boosting the cancer vaccine market growth.
Dendritic cells (DCs) are specialized immune cells that play a vital role in promoting an immune response against foreign pathogens. They are effective inhibitors of the naïve T-cell responses. The Dendritic cell vaccine immunotherapy has its applications involved in major treatments and thus has a wider acceptance across the globe. The technological and innovative advancements in this field are a new ray of hope for the cancer mortality rate to decline.
Increasing novel research centers, understanding of biological mechanisms of the human immune system and cancer, and developing advanced techniques are estimated to create promising opportunities for researchers, physicians, and the market stakeholders. In addition to this, the rising prevalence of cancer cases, increased revenue for healthcare sectors and awareness about the dendritic cell cancer vaccine immunotherapy are also aiding the market growth. The dendritic cell vaccine immunotherapy has revolutionized the market with its exciting and novel range of techniques. In comparison with chemotherapy and radiation therapy, this technique has almost no side effects which are elevating the market towards the north.
The Dendritic Cell cancer vaccine market is achieving heights due to the smart mechanism of action of dendritic cells on cancer cells. Also, increased access to patient data due to advancements in AI is bringing in investments for this market. More than $1.5 Bn has already been invested in this area over the last 5 years.
Segment Analysis
The product type segment for the dendritic cell cancer vaccine is expected to grow at a faster pace, the reason being the demand for Sipuleucel (Provenge) vaccine. Provenge was the first therapeutic vaccine approved by FDA. It was the first marketed vaccine that generated high revenues for the pharmaceutical companies. The market for this is expected to grow from $XX Mn in 2019 to $XX Mn in 2027. It targets prostate cancer by utilizing the patient’s own immune system. The rising cases of prostate cancer are expected to grow the market.
Global Dendritic Cell Cancer Vaccine Market
Market Segmentation
The Global Dendritic Cell Cancer vaccine Market is segmented-
By Product Type
• CreaVax
• Sipuleucel-T (Provenge)
• Others
By End-user
• Paediatrics
• Adults
Regional Insights
Global Dendritic Cell Cancer Vaccine Market1
Based on the regional analysis, North America is estimated to dominate the dendritic cell cancer vaccine market in the forecast period. The first FDA-approved vaccine Provenge has driven the market here, from $XX Mn in 2019 and is expected to reach $XX Mn during the forecast period. The production of vaccines globally is expanding the market size to a greater extent.
In the APAC region, South Africa and India is developing products for other indications. CreaVax of South Africa for prostate cancer and Apceden in India for the solid tumor are developed, growing the market revenue in the APAC region.
In addition to this, Vaccell in Japan, TAP Cells in Chile, MelCancerVac in North America, and Rocapuldencel-T in the US are the vaccines which have entered different phases of clinical trials. These vaccines are expected to be approved soon, enhancing the growth of dendritic cell cancer vaccine market globally.
Key Players operating in the Global Dendritic Cell Cancer Vaccine Market-
• 3M Company
• Batavia Bioservices
• CiMaas
• Activartis
• Dendreon
• Merck KGaA
• GlaxoSmithKline plc
• Northwest Bio therapeutics
• Tella Incorporation
• Creagene
• Immunocellular Therapeutics
• Medigene AG
• HOOKPIA Pharma Inc
• PDC Line Pharma
• Kiromic
• Immunicum
• DCPrime
• DanDrit Biotech
• Elios Therapeutics
• Bellicium Pharmaceuticals
• SOTIO
• Theravectys
• Vaxil Bio therapeutics
• Argos Therapeutics
Competitive Landscape
As per the news released on January 9 2021, CiMaas has received an important stimulus from the Netherlands Enterprise Agency (RVO) for the development of a therapeutic dendritic cell vaccine against lung cancer. It has been approved with a loan of € 2.4 million. According to CiMaas, the loan and previous contributions by investors are enough for performing clinical trials up to 2 phases.
The objective of the report is to present a comprehensive analysis of the Global Dendritic Cell Cancer Vaccine Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give a clear futuristic view of the industry to the decision-makers.
The report also helps in understanding Global Dendritic Cell Cancer Vaccine Market dynamics, structure by analysing the market segments and project the Global Dendritic Cell Cancer Vaccine Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Dendritic Cell Cancer Vaccine Market make the report investor’s guide.
About This Report
For More Information Vist: https://www.maximizemarketresearch.com/market-report/global-dendritic-cell-cancer-vaccine-market/81960/[/b]
Report Is Submitted By : Maximize Market Research Company
Customization of the report:
Maximize Market Research of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.
About Maximize Mark
et Research:
Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.
Contact info
Name: Lumawant Godage
Organization Address: MAXIMIZE MARKET RESEARCH PVT. LTD.
This Report Is Submitted By : Maximize Market Research Company
Address: Omkar Heights, Sinhagad Road, Manik Baug, Vadgaon Bk,Pune, Maharashtra 411051, India.
Contact: +919607195908 8989132284